BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19758507)

  • 1. [The myelodysplastic syndrome and autoimmunity].
    Laursen SB; Nielsen MØ; Hasselbalch HC
    Ugeskr Laeger; 2009 Sep; 171(37):2639-42. PubMed ID: 19758507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survey of exposure to genotoxic agents in primary myelodysplastic syndrome: correlation with chromosome patterns and data on patients without hematological disease.
    Goldberg H; Lusk E; Moore J; Nowell PC; Besa EC
    Cancer Res; 1990 Nov; 50(21):6876-81. PubMed ID: 2208156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between myelodysplastic syndromes and autoimmune disorders.
    Zhao S; Mao H; Wang H; Yu J
    Zhonghua Xue Ye Xue Za Zhi; 2002 Jun; 23(6):311-3. PubMed ID: 12411063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study.
    Giannouli S; Voulgarelis M; Zintzaras E; Tzioufas AG; Moutsopoulos HM
    Rheumatology (Oxford); 2004 May; 43(5):626-32. PubMed ID: 14983106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients.
    Dalamaga M; Karmaniolas K; Matekovits A; Migdalis I; Papadavid E
    J Eur Acad Dermatol Venereol; 2008 May; 22(5):543-8. PubMed ID: 18070024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is thyroid autoimmunity a risk factor for developing primary myelodysplastic syndrome?
    Dalamaga M; Lekka A; Karmaniolas K; Stathopoulou E; Dionyssiou-Asteriou A
    Cancer Causes Control; 2008 May; 19(4):371-8. PubMed ID: 18064534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplastic syndromes: incidence and survival in the United States.
    Ma X; Does M; Raza A; Mayne ST
    Cancer; 2007 Apr; 109(8):1536-42. PubMed ID: 17345612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals.
    Cabello AI; Collado R; Ruiz MA; Martínez J; Navarro I; Ferrer R; Sosa AM; Carbonell F
    Leuk Res; 2005 Apr; 29(4):365-70. PubMed ID: 15725469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No increase in age-specific incidence of myelodysplastic syndromes.
    Germing U; Strupp C; Kündgen A; Bowen D; Aul C; Haas R; Gattermann N
    Haematologica; 2004 Aug; 89(8):905-10. PubMed ID: 15339672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy may unmask hypoplastic myelodysplastic syndrome that mimics aplastic anemia.
    Konoplev S; Medeiros LJ; Lennon PA; Prajapati S; Kanungo A; Lin P
    Cancer; 2007 Oct; 110(7):1520-6. PubMed ID: 17701956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 5q- syndrome and autoimmune phenomena: report of three cases.
    Pinheiro RF; Silva MR; Chauffaille Mde L
    Leuk Res; 2006 Apr; 30(4):507-10. PubMed ID: 16219353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome.
    Yue G; Hao S; Fadare O; Baker S; Pozdnyakova O; Galili N; Woda BA; Raza A; Wang SA
    Leuk Res; 2008 Apr; 32(4):553-8. PubMed ID: 17888511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chromosomal structural changes in patients with myelodysplastic syndrome].
    Yu Y; Liu XP; Liu SH; Yu MH; Zhang Y; Xiao ZJ
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2693-7. PubMed ID: 18167247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers.
    De Roos AJ; Deeg HJ; Davis S
    Cancer Causes Control; 2007 Dec; 18(10):1199-208. PubMed ID: 17823848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered self-reactive antibody repertoires are a general feature of patients with myelodysplastic syndrome.
    Stahl D; Egerer G; Goldschmidt H; Sibrowski W; Kazatchkine MD; Kaveri SV
    J Autoimmun; 2001 Feb; 16(1):77-86. PubMed ID: 11221999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [What to improve in approach to diagnose and treat pediatric myelodysplastic syndromes and juvenile myelomonocytic leukemia in Poland?].
    Wójcik D; Pietras W; Ussowicz M; Chybicka A
    Przegl Lek; 2006; 63(1):29-30. PubMed ID: 16892896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prospective clinical study of diagnosis and classification for 282 cases with primary myelodysplastic syndrome].
    Wang XQ;
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):546-9. PubMed ID: 17172130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions.
    Hasle H; Kerndrup G; Jacobsen BB
    Leukemia; 1995 Sep; 9(9):1569-72. PubMed ID: 7658725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts.
    Voulgarelis M; Giannouli S; Ritis K; Tzioufas AG
    Eur J Clin Invest; 2004 Oct; 34(10):690-700. PubMed ID: 15473894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Auto- and alloreactivity of T lymphocytes in myelodysplastic syndrome].
    Cukrová V; Neuwirtová R; Bartůnková J; Jonásová A; Cermák J; Homolková H; Malíková I
    Cas Lek Cesk; 2006; 145(8):647-52; discussion 653. PubMed ID: 16995421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.